Connor, Clark & Lunn Investment Management (CC&L)
LEGN icon

Connor, Clark & Lunn Investment Management (CC&L)’s Legend Biotech LEGN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,324
Closed -$238K – 1521
2024
Q4 		$238K Buy
7,324
+835
+13% +$34.6K ﹤0.01% 1295
2024
Q3 		$316K Buy
+6,489
New +$346K ﹤0.01% 1221
2023
Q1 		– Sell
-6,596
Closed -$329K – 1364
2022
Q4 		$329K Sell
6,596
-17,535
-73% -$850K ﹤0.01% 965
2022
Q3 		$985K Buy
24,131
+8,727
+57% +$410K 0.01% 660
2022
Q2 		$847K Buy
15,404
+3,921
+34% +$166K 0.01% 658
2022
Q1 		$417K Buy
+11,483
New +$454K ﹤0.01% 812

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s LEGN Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Legend Biotech (LEGN) in Q1 2025, closing a stake of 7,324 shares — an estimated $238K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in LEGN in Q1 2022 and held it in 6 quarters. The position peaked at $985K in Q3 2022. 208 funds tracked by Wall St. Rank hold LEGN as of Q1 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Legend Biotech position as of Q1 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 7,324 Legend Biotech shares in Q1 2025, an estimated $238K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Legend Biotech in Q1 2022 and held it in 6 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Legend Biotech position peaked at $985K in Q3 2022.
  • 208 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.